Germany's economic sentiment hits highest level since early 2022
The ZEW Indicator of Economic Sentiment, which gauges investor expectations for the German economy, rose to 52.7 points this month, up from 47.5 in June and well above economist expectations of 50.3.
This marks the strongest reading since February 2022, shortly before Russia's invasion of Ukraine disrupted global trade and energy flows.
'After the strong improvements of the past two months, the positive sentiment among respondents is becoming more firmly established,' said ZEW President Professor Achim Wambach. 'Despite ongoing uncertainty due to global trade conflicts, nearly two-thirds of the experts expect the German economy to improve.'
Germany's ZEW Current Conditions index rose to -59.5 in July 2025, its highest level since June 2023, up from -72 the previous month and outperforming expectations of -66.
Wambach pointed to hopes of a speedy resolution to the US-EU tariff standoff, alongside the German government's proposed emergency investment programme, as key drivers of optimism.
The upbeat sentiment was particularly notable in expectations for mechanical engineering, metal production and the electrical engineering sector.
The positive sentiment extended to the broader eurozone. The ZEW sentiment index for the single-currency bloc rose modestly to 36.1 in July, up 0.8 points from June.
The assessment of current conditions in the eurozone also improved, though it remained in negative territory at minus 24.2, a 6.5-point gain from the previous month.
Markets steady as trade tensions linger
Financial markets reacted with caution. The euro gained 0.2% against the US dollar to $1.1680, on track to snap a four-day losing streak.
Bund yields dropped 3 basis points to 2.69%, after hitting on Monday their highest levels since early April.
Still, investor nerves were apparent after US President Donald Trump announced a new 30% tariff on European Union imports from 1 August. The European Commission has pledged to intensify negotiations to avert a trade-war escalation.
Germany's DAX index was unchanged at 24,200 points, consolidating after three consecutive sessions of losses. The broader Euro STOXX 50 rose 0.3%, supported by strength in industrial and automotive names.
Among top gainers, ASML Holding advanced 2.4%, followed by BASF (1.92%), Mercedes-Benz (1.74%), Volkswagen (1.45%) and BMW (1.44%). On the downside, L'Oréal fell 1.35%, Orange slipped 1.23% and Telefónica declined 0.91%.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Euronews
an hour ago
- Euronews
Moldovan oligarch accused of €850m bank fraud detained in Greece
A fugitive oligarch from Moldova accused of a $1 billion (€850 million) bank fraud and other illicit schemes was detained in Greece on Tuesday, Moldova's national police said. Vladimir Plahotniuc fled Moldova in 2019, as he faced a series of corruption charges, including allegations of complicity in a scheme that led to $1 billion disappearing from a Moldovan bank in 2014, which at the time was equivalent to around one-eighth of the country's annual GDP. Plahotniuc has denied any wrongdoing. Moldovan police said in a statement they were informed by Interpol's office in Athens that two Moldovan citizens had been detained, including Plahotniuc, who was placed on Interpol's international wanted list in February. Authorities did not name the other detainee. The Greek police unit tackling organised crime said Interpol was seeking Plahotniuc on suspicion of participating in a criminal organisation, fraud and money laundering. Moldova's Ministry of Justice and Prosecutor's Office are in the process of exchanging information to begin seeking extradition of Plahotniuc and the other detainee, a government official told AP. Plahotniuc, one of Moldova's wealthiest men, fled to the US from Moldova in June 2019 after failing to form a government with his Democratic Party. The US declared him persona non grata in 2020, and his whereabouts were unknown for years. The influential businessman and politician was added to a US State Department sanctions list in 2022 for alleged corruption. The charges included controlling the country's law enforcement to target political and business rivals and meddling in Moldova's elections. He was added to a UK sanctions list in 2022 and barred from entering the country. His assets were frozen in Britain and its overseas territories. Plahotniuc was accused of involvement in pro-Russian political campaigns and efforts to derail Moldova's pro-EU course. The news of his arrest is likely to be viewed positively by President Maia Sandu's camp and her Romanian and EU supporters ahead of September's crucial parliamentary elections, in which the Kremlin is already involved through proxies in massive disinformation and voter manipulation campaigns.
France 24
an hour ago
- France 24
AstraZeneca to invest $50 bn in the US as tariff threat looms
The funds will boost its manufacturing and research operations in the US, including the construction of a multi-billion-dollar factory in Virginia, the company said in a statement. "Today's announcement underpins our belief in America's innovation in biopharmaceuticals," chief executive Pascal Soriot said in a statement. US President Donald Trump has opened the door to potential tariffs targeting pharmaceuticals, which had up to now benefited from exemptions to his sweeping levies on imports from trading partners. He ordered an investigation into pharmaceutical imports, suggesting that levies could reach up to 200 percent. The United States is a key market for the pharmaceutical industry, and AstraZeneca said it expects 50 percent of its revenue to come from the US by 2030. AstraZeneca has already begun transferring part of its European production to the United States, it announced in April. While the drugmaker could become exposed to US levies on its European-made products, Soriot has said that the impact would be limited due to the ongoing shift in production. 'Losing patience' Other major pharmaceutical companies, which had been exempt from tariffs for 30 years, have in recent months begun shifting investment and production to the United States. Swiss pharmaceutical giants Roche and Novartis and France's Sanofi have all announced multi-billion-dollar investments in the US. "For decades, Americans have been reliant on foreign supply of key pharmaceutical products," US Commerce Secretary Howard Lutnick said in a statement. He added that the new tariffs are focused on "ending this structural weakness". Tuesday's announcement included a new factory in Virginia, which will be the company's "largest single manufacturing investment". It adds to AstraZeneca's previously announced $3.5 billion investment in the US by 2026. "Soriot implied... that AstraZeneca wasn't wedded to a particular country and that it would invest wherever it made financial sense," said AJ Bell investment director Russ Mould. However, he noted that "the more business it does in the country, the greater the likelihood that investors might push for AstraZeneca to switch its main stock listing to the US." The pharmaceutical company abandoned plans earlier in the year to build a £450 million ($606 million) vaccine plant in the UK city of Liverpool, citing timing issues and a reduction in subsidies offered by the government. The move "was the big clue that it was losing patience with the UK government," said Mould. © 2025 AFP
Fashion Network
2 hours ago
- Fashion Network
Global businesses eye US expansion to lessen fallout from tariffs
Some non-US companies have said they are looking at expanding their presence or setting up shop in the US to mitigate the impact of President Donald Trump 's tariffs, including businesses in the fashion and personal care sectors. Below are some of the plans flagged by those companies. ESSITY The Swedish hygiene product maker could move more of its production into the US from Mexico and Canada, its CEO said in January. LVMH The luxury conglomerate is "seriously considering" bulking up its US production capacities, its CEO said in January. ROCHE The Swiss pharmaceutical giant will invest $50 billion in the US over the next five years, it said in April. On May 12, it announced additional $550 million investment to expand its Indianapolis diagnostics manufacturing hub.
